Susquehanna International Group’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-155,188
| Closed | -$128K | – | 13239 |
|
|
2025
Q1 | $128K | Buy |
155,188
+33,320
| +27% | +$32.1K | ﹤0.01% | 11352 |
|
|
2024
Q4 | $116K | Buy |
121,868
+71,619
| +143% | +$67.6K | ﹤0.01% | 11224 |
|
|
2024
Q3 | $50.2K | Sell |
50,249
-54,036
| -52% | -$59.8K | ﹤0.01% | 11372 |
|
|
2024
Q2 | $129K | Buy |
+104,285
| New | +$106K | ﹤0.01% | 10837 |
|
|
2024
Q1 | – | Sell |
-45,443
| Closed | -$56.8K | – | 12794 |
|
|
2023
Q4 | $56.8K | Buy |
+45,443
| New | +$50.3K | ﹤0.01% | 11668 |
|
|
2023
Q3 | – | Sell |
-10,968
| Closed | -$17.7K | – | 12510 |
|
|
2023
Q2 | $18.9K | Sell |
10,968
-115,815
| -91% | -$184K | ﹤0.01% | 11651 |
|
|
2023
Q1 | $185K | Buy |
126,783
+103,455
| +443% | +$198K | ﹤0.01% | 10695 |
|
|
2022
Q4 | $37.8K | Buy |
23,328
+10,961
| +89% | +$25.2K | ﹤0.01% | 11540 |
|
|
2022
Q3 | $41K | Sell |
12,367
-34,289
| -73% | -$155K | ﹤0.01% | 12318 |
|
|
2022
Q2 | $170K | Buy |
46,656
+19,000
| +69% | +$86.1K | ﹤0.01% | 10872 |
|
|
2022
Q1 | $200K | Sell |
27,656
-2,407
| -8% | -$20.5K | ﹤0.01% | 11236 |
|
|
2021
Q4 | $409K | Buy |
+30,063
| New | +$470K | ﹤0.01% | 9710 |
|
Susquehanna International Group's KRON Position: Q2 2025 in Review
Susquehanna International Group sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 155,188 shares — an estimated $128K sold.
Susquehanna International Group first reported a position in KRON in Q4 2021 and held it in 12 quarters. The position peaked at $409K in Q4 2021. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- Susquehanna International Group reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- Susquehanna International Group sold 155,188 Kronos Bio shares in Q2 2025, an estimated $128K.
- Susquehanna International Group first reported a position in Kronos Bio in Q4 2021 and held it in 12 quarters.
- Susquehanna International Group's Kronos Bio position peaked at $409K in Q4 2021.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.